Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury.

ABSTRACT:

Unlabelled

More than 6.5 million patients are burdened by the physical, cognitive, and psychosocial deficits associated with traumatic brain injury (TBI) in the U.S. Despite extensive efforts to develop neuroprotective therapies for this devastating disorder, there have been no successful outcomes in human clinical trials to date. Retrospective studies have shown that β-adrenergic receptor blockers, specifically propranolol, significantly decrease mortality of TBI through mechanisms not yet fully elucidated but are thought to counterbalance a hyperadrenergic state resulting from a TBI. Conversely, cellular therapies have been shown to improve long-term behavior following TBI, likely by reducing inflammation. Given the nonredundancy in their therapeutic mechanisms, we hypothesized t

SUBMITTER: Kota DJ 

PROVIDER: S-EPMC4704870 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature